Zuo Zhao
Zuo Zhao has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Abhik Mukherjee
Department of Histopathology, Division of Cancer and Stem cells, School of Medicine, University of Nottingham, Nottingham, UK
36 shared publications - Ajay Sudan
Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
36 shared publications - Alice Dewdney
11Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
36 shared publications - Amir Montazeri
The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom
36 shared publications - Andrea Muranyi
Ventana Medical Systems, Inc./Roche Tissue Diagnostics, Tucson, Arizona
36 shared publications - Ann O'CAllaghan
16Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom
36 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
Representativeness of study participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
Representativeness of study participants
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
Example AREG and EREG immunohistochemistry
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
Example AREG and EREG immunohistochemistry
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
AREG/EREG with variation in tissue processing
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
AREG/EREG with variation in tissue processing
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
Example AREG and EREG immunohistochemistry
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer
Example AREG and EREG immunohistochemistry